Introduction
The recent introduction of deep sequencing technology, capable of detecting sequences of hundreds of thousands of individual molecules, is rapidly changing the landscape of cancer genome research. Comprehensive genome analyses using the deep sequencing technique have clarified that each tumor cell has numerous nucleotide alterations 1 . Among the genetic aberrations, driver mutations are thought to contribute to tumorigenesis by conferring a selective advantage to the cell. On the other hand, passenger mutations are defined as those that do not alter fitness but occur in a cell that coincidently, or subsequently, acquired a driver mutation 2 .
Recent reports demonstrated that human gastric cancer has approximately 66 to 212 mutations in coding regions, and only a few of them are considered driver mutations [3] [4] [5] [6] . Among them, mutations in the tumor suppressor TP53 gene are the most common driver mutations in human gastric cancer tissues. A second common putative driver mutation was determined in the chromatin remodeling complexes gene, ARID1A 3 . It remains unclear, however, when and how those driver mutations emerge in the gastric epithelium during tumorigenesis.
Epidemiologic studies revealed that patients with Helicobacter pylori (H pylori) infection have a significantly increased risk of gastric cancer compared to H pylori-negative individuals 7, 8 .
The more prevalent form of gastric adenocarcinoma frequently progresses through a series of histologic steps that are initiated by chronic gastritis, which then leads to atrophic gastritis and intestinal metaplasia, and finally to dysplasia and adenocarcinoma in individuals with H pylori infection 9 . Multicentric tumor development characterized in H pylori-associated gastric cancer 10 suggests that the H pylori-infected stomach could include epithelial cells and/or intestinal metaplasia with genetic damage that possess high susceptibility to tumor development 11 .
Consistent with these findings, animal experiments using Big Blue mice revealed a high mutation frequency in the H pylori-infected gastric mucosa 12 , which are increased in emergence of genetic alterations in H pylori-infected gastric mucosa, however, has not been elucidated. We recently demonstrated that H pylori infection and the resultant chronic inflammation with mononuclear cell infiltration induces genetic alterations, including somatic mutations and chromosomal aberrations, in gastric epithelial cells through the expression of a DNA-mutator enzyme, activation-induced cytidine deaminase (AID) [14] [15] [16] [17] . In vitro studies revealed that H pylori infection elicited the ectopic expression of AID in association with a high mutation frequency of the TP53 genome sequences 14 . To date, however, there has not been enough evidence showing that AID expression in gastric mucosa in vivo causes the accumulation of driver mutations in the human TP53 sequences required for malignant transformation.
To clarify the mechanisms underlying the contribution of inflammation to carcinogenesis, it is important to identify the genetic alterations that occur in the inflamed epithelium before the onset of tumorigenesis. The main obstacle to detecting latently accumulated genetic alterations in non-tumorous inflamed tissue is the diversity and low frequency of the mutated genes 18 . In the present study, to unveil the landscape of accumulated genetic aberrations in chronically inflamed gastric epithelium, we performed whole exome sequencing and additional deep sequencing of the inflamed gastric mucosa with chronic H pylori infection. Furthermore, to confirm whether constitutive AID expression in vivo contributes to the emergence of the TP53 mutations, we determined the mutation profile of the TP53 gene in the AID-expressing gastric mucosa of the human TP53 knock-in mouse model.
Materials and methods
Whole exome capture and massively-parallel sequencing.
Massively-parallel sequencing was performed as described previously 19, 20 . Figure 1 and Supplementary materials and methods). To validate somatic mutations, we performed PCR-based deep-sequencing using a different deep-sequencing platform (the GS Junior System, Roche) on the non-silent mutations detected by whole exome sequencing, according to the validation protocol reported in the recent study 21 .
We estimated that the reliabilities of whole exome sequencing were 88.6% for somatic mutations detected in the tumor tissues and 86.4% for somatic mutations detected in the non-tumor tissues (data not shown). Primer sequences are shown in Supplementary Table 1 .
Deep sequencing on selected genes.
The mutational status of TP53, ARID1A, MLL2, SUV39H1, CTNNB1, PIK3CA, and TP53
cDNA was investigated by high-coverage sequencing analyses. Target regions were designed within the range from 330 to 520 bp. The primer sequences are described in Supplementary was dA-tailed and ligated with adaptors containing tag sequences, followed by emulsion PCR and sequencing using the GS Junior System (Roche) according to the manufacturer's protocol.
Deep sequencing data were analyzed with NextGENe software. We identified low-abundance somatic mutations by the strict variant filtering process (Supplementary Figure 2 and Supplementary materials and methods). Candidate low-abundance mutations were validated by repeated deep sequencing using independent amplicons derived from the same samples.
Tissue specimens and DNA extraction.
Animal Experiments.
Whole exome sequencing analysis and variant filtering.
Deep sequencing analysis and variant filtering.
Functional prediction analysis and pathway analysis.
Statistical analysis.
These procedures and information are described in the Supplementary Materials and Methods.
Results
Landscape of genetic alterations that accumulated in H pylori-associated gastric cancers. Table 4 ). According to the variant filtering process (Supplementary Figure 1) , we identified single nucleotide variants (SNVs), short insertions and deletions (indels) in cancer tissues as well as in the non-cancerous gastritis mucosa.
We identified 892 somatic mutations in 793 genes in the 5 gastric cancer tissues. The identified mutations included 654 non-silent mutations (552 missense, 25 nonsense, 1 stop codon loss, 11 essential splice site mutations, and 65 indels) and 238 synonymous mutations (Supplementary Tables 5, 6 ). The number of non-silent mutations in the MSI gastric cancer sample was significantly higher than those of any of the MSS tumor samples ( Figure 1A ). In addition, the MSI tumor also had a large number of indels, while the MSS tumors had only a few indels ( Figure 1C , Supplementary Table 5 ). Furthermore, the mutation frequency at each nucleotide position in the MSI tumor tended to be higher than those in the MSS tumors ( Figure   1B ). These findings indicated that MSI gastric cancers have enhanced genetic aberrations compared with MSS tumors.
Mutation profiles of MSS and MSI gastric cancer tissues.
Among the mutated genes identified, 26 genes were recurrently mutated as non-synonymous mutations or indels in two or more gastric cancers (Table 1 ). These genes included TP53
(mutated in 3 of 5 cases), and ARID1A (mutated in 2 of 5 cases), mutations of which were mutually exclusive 3, 4 . All of the TP53 mutations were present as a type of nucleotide substitution in three MSS tumor tissues, whereas the ARID1A mutations were detected as deletions in the one remaining MSS and in one MSI gastric cancer. Pathway analyses in the five gastric cancers revealed that cell adhesion 4 was the most significantly enriched biological process, followed by metabolic processes, endocytosis and extracellular structure organization (Supplementary Table   7 ).
Recent studies showed that the pattern of nucleotide alterations could provide a clue to determine the molecular process underlying mutation occurrence [22] [23] [24] [25] [26] [27] . We first confirmed that over half of the SNVs that accumulated in the exome sequences of gastric cancer tissues were enriched with a C:G>T:A transition (p<0.01 by ANOVA, Figure 1C ). The prevalence of these C:G>T:A transitions in the MSI gastric cancer was substantially higher than that in the MSS tumors (65.1% vs. 48.9%, respectively). These mutational signatures suggested that cytidine to uracil deamination is deeply implicated in the mutational process underlying H pylori-associated gastric carcinogenesis. Among the cytidine deaminase family proteins, AID exhibits a strong preference for deaminating C residues flanked by a 5'-purine (G or A) 22, 28, 29 . In contrast, APOBEC3 family enzymes and APOBEC1 favor C residues flanked by 5'-T 30, 31 . Therefore, we further evaluated the sequence characteristics flanking the mutated C residues in tumor tissues.
Consistent with the previous report 5 , we found that the GpCpX (C is the mutated nucleotide and X is any base, GpCpA: 23.9%, GpCpC: 24.3%, GpCpG: 38.4%, GpCpT: 13.4%) pattern dominated across all of the tissues examined (p<0.01 by ANOVA), followed by CpCpX and ApCpX ( Figure 1D ), suggesting that deamination achieved by AID activity is likely to be involved in the mutational signature of H pylori-associated gastric cancers.
Overview of genetic alterations that accumulated in non-cancerous gastritis mucosa with H pylori infection.
Whole exome sequencing clarified that various mutations were also present in the non-cancerous H pylori-infected gastritis mucosa. All of the mutations detected in the non-tumorous gastric mucosa were SNVs and no indels were observed in any of the non-tumorous gastritis tissues. The mean number of mutated genes in the non-tumorous tissues was 28.4 per sample, which was lower than that in the matched tumor tissues of all 5 patients (Supplementary Tables 5, 8 ). In addition, the mutation frequency at each nucleotide position represented less than 20% of the total reads of the majority of the altered genes in non-tumorous gastric mucosa ( Figure 1B ), indicating that the mutation frequency at each nucleotide position tended to be lower in the non-cancerous tissues than in the cancer tissues. The total number of mutated genes and mutant allele frequencies in the non-tumorous tissues did not significantly differ between the patient with MSI and those with MSS cancers ( Figure 1A , 1B, Supplementary Table 9 ). Whole exome sequencing also revealed 25 genes that were commonly mutated in both the tumor and the matched background gastritis mucosa of the same patients (Supplementary   Tables 10 and 11 ). Among them, 16 genes acquired non-synonymous mutations and Sanger sequencing confirmed that those SNVs were not detected in the matched control lymphocytes, while the biological role of these mutated genes remains unclear.
Establishment of deep sequencing platform for detecting low-abundance mutations in
tumor-related genes.
Whole exome sequencing clarified that somatic mutations accumulated in various genes in H pylori-infected gastritis mucosa, while the majority of the mutated genes detected were supposed to be "passenger" mutations. Those findings prompted us to examine whether somatic mutations latently accumulate in "driver" genes that could contribute to gastric tumorigenesis, and thus deep sequencing analysis of the selected amplicons of tumor-related genes were applied to the non-tumorous gastric mucosa and the matched peripheral lymphocytes from H pylori (+) patients with and without gastric cancers.
First, we conducted control experiments to validate the efficacy and error rates in deep sequencing using a plasmid encoding the TP53 cDNA sequence as a template. The deep sequencing platform provided us the TP53 sequences derived from the plasmids with a mean coverage of 4024 at each nucleotide site and the error rate per nucleotide position was below 0.07%. To estimate the accuracy of detecting nucleotide alterations using reads filtered by mean base quality and mapping quality, we introduced expression plasmids with a single point mutation within this wild-type sequence with a ratio of 1%(1:100), 0.1%(1:1000), or 0.01%(1:10000). Duplicate control experiments revealed that mutations present at an input ratio of 0.1% were detected ranging between 0.11% and 0.12% (Supplementary Table 12 ). Based on these results, the limit of mutant allele frequencies detectable by this deep sequencing was considered to be more than 0.1% of the total reads. Finally, to exclude the errors during the sequencing process, repeated experiments were performed and we determined that nucleotide alterations validated by at least more than two different deep sequencings were low-abundance somatic mutations.
Somatic mutations accumulated in tumor-related genes in H pylori infection-related gastritis mucosa.
We performed deep sequencing on the selected amplicons of tumor-related genes in H pylori-related gastritis mucosa in 28 patients with gastric cancer and 6 patients without gastric cancer (Supplementary Table 13 ). Consistent with the previous studies 3, 4 , our whole exome sequencing on 5 tumor tissues identified that TP53 and ARID1A were frequently mutated in gastric cancer tissues. In addition, the previous studies clarified that CTNNB1 and PIK3CA are also frequently mutated in gastric cancer tissues 3, 4 . Based on those findings, we selected these four genes (TP53, ARID1A, CTNNB1 and PIK3CA) for further deep-sequencing analyses. In addition, we targeted MLL2 and SUV39H1, which were identified by current whole exome sequencing in non-cancerous gastritis tissues. The mean coverage ranged from 2319 to 12,934
fold at each targeted gene.
We first verified that no nucleotide alterations were detected in normal gastric mucosa without H pylori infection or any lymphocytes of the enrolled patients. Deep sequencing on 34 gastritis mucosa revealed that a lot of non-synonymous mutations were present at a very low frequency (0.11-1.12%) in various genes (p<0.05 by χ 2 test). We validated the results by repeated deep sequencings and confirmed that 83.7% of the nucleotide changes detected by the initial analyses were also detected by the independent deep sequencing analyses (Supplementary Table 14 ). In the gastritis mucosa of 28 patients with gastric cancer, we identified non-synonymous low-abundance mutations in 13 nucleotide positions of TP53 in 11 cases, 6 positions of ARID1A in 4 cases, and 3 positions of MLL2 in 2 cases, while no mutations were detected in CTNNB1, PIK3CA, and SUV39H1 (Table 2 ). In addition, in the gastritis mucosa of 6 patients without gastric cancer, non-synonymous low-abundance mutations were detected in 6 positions of TP53 in 4 cases and in 1 position of ARID1A in 1 case (Table 3) . 
Mutation signature induced by AID activity that accumulated in human TP53 genes in vivo.
The mutation spectrum determined in the TP53 sequences supported the possibility that AID-mediated deamination activity is deeply involved in the induction of driver mutations in tumor-related genes during human gastric carcinogenesis. To gain further insight into the role of AID in the emergence of somatic mutations in vivo, we determined the nucleotide sequences of the human TP53 genes in the gastric mucosa of the human TP53 knock-in (Hupki) mice 33 after crossing them with AID transgenic (Tg) mice using deep sequencing analysis. Although the mean coverage reached 6434-fold, only one low-abundance mutation was detected in the human TP53 sequences from the gastric mucosa of 6 control Hupki mice with any type of codon 72 polymorphic variant (codon72 Arg/Arg, Pro/Pro and Arg/Pro) ( Table 4 ). In contrast, low-abundance mutations accumulated in the human TP53 gene sequences in the gastric mucosa of 6 of 7 (85.7%) Hupki/AID-Tg mice (p=0.053 by χ 2 test, Table 4 ). 8 of 9 (88.9%) genetic alterations determined in the gastric mucosa of 6 Hupki/AID-Tg mice were C:G>T:A transitions at the GpCpX motif (p<0.01 by χ 2 test). Moreover, numbers of the low-abundance TP53 mutations were identical to the amino acid positions altered in human gastric cancer tissues 34, 35 ( Figure 2D ). These findings provide evidence that the AID-mediated cytidine deamination could be deeply involved in the nucleotide alterations of the human TP53 gene that accumulate in the gastric mucosa during gastric tumorigenesis.
Discussion
Chronic inflammation plays a critical role as a background of cancer development 16, 36, 37 .
Therefore, it is reasonable to assume that stepwise accumulation of genetic alterations that contribute to tumorigenesis occurs in chronically inflamed epithelial cells. Consistently, several studies have reported that genetic aberrations are frequently detected in non-tumorous inflamed epithelial tissues where the risk of cancer development is remarkably high [38] [39] [40] . For example, TP53 mutations are detected in the inflamed mucosa of the colonic epithelium of patients with inflammatory bowel disease 41, 42 . A recent sequencing study on Barrett's esophagus revealed that the mutational profiles of Barrett's esophagus and esophageal adenocarcinoma are remarkably similar, suggesting that genetic alterations in the metaplasia-carcinoma sequence of Barrett's esophagus occur much earlier than the histologic changes of frank dysplasia 40 . In the present study, using a whole exome sequencing technique, we demonstrated that somatic mutations accumulated not only in tumors but also in the non-tumorous inflamed gastric mucosa infected with H pylori.
Regarding the cancer tissues, whole exome sequencing determined a remarkable difference in the mutation signature between MSI and MSS tumors. Namely, MSS tumors possessed a relatively lower number of total mutations, including SNVs and indels, compared with the MSI tumor. Indeed, the 4 MSS gastric cancer samples had an average of 56 non-silent somatic mutations with few indels, while the MSI gastric cancer sample had 427 non-silent somatic mutations including a large number of indels, consistent with the previous reports 3, 6 . Moreover, the frequency of mutations at each nucleotide position in the MSS cancers tended to be lower than that in the MSI tumor. Notably, the mutation signature in non-tumorous background gastric mucosa did not differ significantly between patients with MSS and MSI tumors. These findings suggest that the outstanding features of genetic instability characterized as MSS and MSI phenotypes were not evident in the premalignant condition of gastric mucosa underlying H pylori infection and resultant chronic inflammation, and would only become evident in the tumor cells after malignant transformation. Since the allelic fraction is highly dependent on the cell purity in the tissue samples, we should pay attention to the possibility that the tumor or epithelial cell purity could cause differences in the mutation frequencies in each tissue specimen analyzed.
Whole exome sequencing also clarified that the somatic mutations in various genes were latently accumulated in the non-tumorous gastritis mucosa of patients with H pylori infection. It is notable that the total number of mutated genes of the non-tumorous gastric mucosa was smaller than that of the matched tumor tissues and the majority of the mutations detected in gastritis mucosa were predicted to have no influence on cell behavior, suggesting that most of the mutations in gastritis mucosa were passenger mutations. To unveil whether mutations of driver genes were present in gastritis mucosa, we conducted deep sequencing of the selected target genes on H pylori (+) gastric epithelium. The sensitivity of ultra-deep sequencing analysis is primarily limited by errors introduced during any process of the sample preparation and the sequencing reaction, including PCR amplification, cluster amplification, cycle sequencing, image analysis, and others; thus, it is a challenge to distinguish rare mutations from sequencing artifacts 18 . In the present study, we optimized the deep sequencing by defining a strict filter setting and confirmed that no nucleotide alterations over the cut-off were detected in the control lymphocytes or in normal gastric mucosa. Furthermore, we validated the results by repeating the deep sequencing using independent amplicons derived from the same patients, although errors cannot completely be ruled out. Through these strict validation processes, we reproducibly Recent studies showed that the mutation signature that accumulates in tumor tissues provides the clue to identifying the cause of genetic alterations during tumor development [22] [23] [24] [25] [26] [27] 43 . It was shown that C:G>T:A transitions at XpCpG trinucleotides were especially prominent in many cancer types 27, 44 . Among the C:G>T:A transitions, the footprint of AID is characterized by C:G>T:A alterations that occur in GpCpX or ApCpX sequences 22, 28, 29, [45] [46] [47] . In the current study, previously established mouse models with inflammation-associated gastric carcinogenesis [50] [51] [52] .
In summary, we demonstrated that various mutations were latently accumulated in the gastric mucosa in patients with H pylori infection. The combination of whole exome sequencing with deep sequencing enabled us to unveil the landscape of mutations that latently accumulated in non-tumorous gastritis mucosa. Interestingly, the mutation signature not only in gastric cancer genomes but also in gastritis mucosa suggested that AID-mediated deamination events were predominant during the process of gastric carcinogenesis. In particularly, a causal relationship between AID activity and the accumulation of TP53 mutations was also validated by in vivo models. It is expected that uncovering the landscape of genetic alterations in gastritis mucosa will contribute to clarifying the mechanism of gastric cancer development. 
